13 July 2021director interest notice● Neutral
Laura Pitlik became a Arcadia Biosciences, Inc. Chief Marketing Officer and company insider (initial ownership filing).
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
6 July 2021asset acquisition disposition▲ GoodMajor
Arcadia sold all of its remaining BIOX shares -- $17,970,303 in a block sale to 5D+ Draco I Latam Income Plus, plus $4,125,403 more in open-market sales -- fully cashing out the equity portion of the November 2020 Bioceres deal for roughly $22.1 million combined, on top of the original $5 million cash and ongoing royalties.
4 June 2021director interest notice● Neutral
Arcadia Biosciences, Inc. director Amy Yoder received a stock option grant for 10,935 shares.
4 June 2021director interest notice● Neutral
Arcadia Biosciences, Inc. director Lilian Shackelford Murray received a stock option grant for 10,935 shares.
4 June 2021director interest notice● Neutral
Arcadia Biosciences, Inc. director Deborah D Carosella received a stock option grant for 10,935 shares.
4 June 2021director interest notice● Neutral
Arcadia Biosciences, Inc. director Albert D. Bolles received a stock option grant for 10,935 shares.
4 June 2021director interest notice● Neutral
Arcadia Biosciences, Inc. director Kevin Comcowich received a stock option grant for 25,514 shares.
4 June 2021director interest notice● Neutral
Arcadia Biosciences, Inc. director Gregory D Waller received a stock option grant for 10,935 shares.
21 May 2021asset acquisition disposition▲ GoodMajor
Arcadia acquired substantially all assets of three CBD/wellness brands (Eko Holdings, Lief Holdings, Live Zola) through new subsidiary Arcadia Wellness for $4 million cash plus 827,400 shares -- expanding beyond the Archipelago Hawaii JV into owned CBD consumer brands -- and hired a new Chief Growth Officer to run the business.
20 May 2021director interest notice● Neutral
Chris Cuvelier became a Arcadia Biosciences, Inc. Chief Growth Officer and company insider (initial ownership filing).
20 May 2021director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Growth Officer Chris Cuvelier received a stock option grant for 100,000 shares.
17 May 2021quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $828 thousand and net income of $2.1 million for the period ended 2021-03-31.
17 May 2021quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $828 thousand and net income of $2.1 million for the period ended 2021-03-31.
24 Feb 2021director interest notice● Neutral
Deborah D Carosella became a Arcadia Biosciences, Inc. director and company insider (initial ownership filing).
24 Feb 2021director interest notice● Neutral
Arcadia Biosciences, Inc. director Deborah D Carosella received a stock option grant for 21,853 shares.
16 Feb 2021securities registration● Neutral
Arcadia Biosciences, Inc. filed notice of an exempt private placement.
12 Feb 2021securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
10 Feb 2021substantial holder notice● Neutral
Hudson Bay Capital Management LP, Sander Gerber reported a Arcadia Biosciences, Inc. shareholding of 890,049 shares (6.21% of votes) in a periodic institutional filing.
2 Feb 2021securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC using its shelf eligibility.
29 Jan 2021capital raising announcement▲ GoodMajor
Arcadia's largest financing yet: 7,876,784 shares at $3.1925 plus warrants for another 3.9 million shares, with a registration rights agreement obligating the company to register the shares for resale by specific deadlines or pay liquidated damages.
What it means for a shareholder
7.9m new shares at US$3.19 to raise about US$25.1m. That's 37% dilution: every existing holder's slice gets 37% smaller. If you held US$1,000 of shares (313 at the issue price), your slice goes from 0.00233% to 0.00147% of the company. To keep it you'd need 183 more shares - about US$584 at the issue price.
Create a free account to see this worked out for your own holding.
29 Jan 2021substantial holder notice● Neutral
Mitchell P. Kopin, Daniel B. Asher, Intracoastal Capital LLC reported a Arcadia Biosciences, Inc. shareholding of 745,324 shares (5.30% of votes) in a periodic institutional filing.
25 Jan 2021director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Matthew T Plavan received 250,000 shares as an equity award and bought 585 shares on the open market.
25 Jan 2021director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Technology Officer Randall Shultz received 55,000 shares as an equity award and bought 700 shares on the open market.
25 Jan 2021director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Pamela Haley received 85,000 shares as an equity award and bought 700 shares on the open market.
22 Dec 2020securities registration● Neutral
Arcadia Biosciences, Inc. filed a prospectus supplement for an offering off its existing shelf.
22 Dec 2020capital raising announcement▼ Bad
Another Wainwright-placed offering, 2,618,658 shares at $2.93 -- the lowest price yet in this recurring financing pattern.
What it means for a shareholder
2.6m new shares at US$2.93 to raise about US$7.7m. That's 19% dilution: every existing holder's slice gets 19% smaller. If you held US$1,000 of shares (341 at the issue price), your slice goes from 0.00315% to 0.00254% of the company. To keep it you'd need 83 more shares - about US$243 at the issue price.
Create a free account to see this worked out for your own holding.
18 Nov 2020asset acquisition disposition▲ GoodMajor
Arcadia exited its 50/50 Verdeca joint venture with Bioceres, selling its stake to Bioceres Crop Solutions Corp (BIOX) for $5 million cash plus 1.875 million BIOX shares, with up to $3 million more in milestone payments and ongoing royalties (6% on HB4 soybean sales, 25% on wheat sales, capped at $10 million) -- converting a capital-intensive JV into a licensing/royalty relationship with BIOX for South and Central America.
13 Nov 2020quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $314 thousand and a net loss of $6.4 million for the period ended 2020-09-30.
12 Nov 2020quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $314 thousand and a net loss of $6.4 million for the period ended 2020-09-30.
11 Sept 2020securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.